Penn Davis Mcfarland Inc. Has $2.54 Million Holdings in Becton, Dickinson and Company $BDX

Key Points

• Penn Davis Mcfarland Inc. increased its holdings in Becton, Dickinson and Company by 81.3%, now owning 14,758 shares valued at approximately $2.54 million.
• Institutional investors own about 86.97% of Becton, Dickinson and Company's stock, with notable recent investments from several financial firms.
• Analysts have generally assigned a "Hold" rating to the stock, with a consensus target price of $213.30, while shares currently trade around $185.92.

Penn Davis Mcfarland Inc. raised its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 81.3% during the second quarter, according to its most recent filing with the SEC. The firm owned 14,758 shares of the medical instruments supplier's stock after purchasing an additional 6,620 shares during the period. Penn Davis Mcfarland Inc.'s holdings in Becton, Dickinson and Company were worth $2,542,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Saudi Central Bank acquired a new stake in Becton, Dickinson and Company during the 1st quarter worth about $26,000. Smallwood Wealth Investment Management LLC bought a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at about $27,000. Alpine Bank Wealth Management acquired a new stake in Becton, Dickinson and Company during the first quarter worth approximately $29,000. Cornerstone Planning Group LLC lifted its stake in Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after buying an additional 99 shares during the period. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new position in Becton, Dickinson and Company in the first quarter valued at approximately $31,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Claire Fraser sold 917 shares of the company's stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director owned 22,226 shares in the company, valued at $4,167,375. This represents a 3.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares of the company's stock, valued at approximately $881,077.23. This represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 2,965 shares of company stock worth $551,536 over the last ninety days. Insiders own 0.36% of the company's stock.

Wall Street Analysts Forecast Growth

BDX has been the subject of several research analyst reports. Piper Sandler reiterated a "neutral" rating and issued a $200.00 price objective (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Morgan Stanley upped their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Barclays reduced their target price on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research note on Tuesday, June 3rd. Argus boosted their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Finally, Wells Fargo & Company increased their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a report on Friday, August 8th. Four investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, Becton, Dickinson and Company presently has a consensus rating of "Hold" and a consensus target price of $213.30.

Becton, Dickinson and Company Trading Down 0.3%

BDX opened at $185.92 on Thursday. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The firm has a market capitalization of $53.29 billion, a PE ratio of 33.44, a P/E/G ratio of 1.50 and a beta of 0.27. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The company's 50-day moving average is $188.15 and its 200 day moving average is $189.56.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. The firm had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company's revenue for the quarter was up 10.4% on a year-over-year basis. During the same period in the previous year, the company posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be paid a dividend of $1.04 per share. The ex-dividend date is Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio (DPR) is 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.